OBJECTIVE： To explore the clinical efficacy and safety of nedaplatin combined with docetaxel in  the treatment of advanced cervical cancer. METHODS： A total of 53 patients with advanced cervical cancer selected from our hospital during Apr. 2014-Apr. 2016 were divided into observation group （31 cases） and control group （22 cases） according to chemotherapy plan. Control group was given Docetaxel injection 60 mg/m2， ivgtt，qw. Observation group was additionally given Nedaplatin for injection 35 mg/m2+0.9％ Sodium chloride injection diluted into 500 mL， ivgtt （≥60 min）， qw. A chemotherapy cycle lased for 21 d， and both groups received 2 cycles of chemotherapy. Clinical efficacies of 2 groups were evaluated 2 weeks after treatment， and the level of PCNA integal was detected before and 2 weeks after treatment. The occurrence of ADR was recorded. RESULTS： The total response rate of observation group （77.42％） was significantly higher than that of control group （63.64％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in PCNA integval between 2 groups （P＞0.05）. After treatment， PCNA integval of 2 groups were decreased significantly， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）.  ADR were concentrated in grade I， and there was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Docetaxel combined with nedaplatin can significantly improve the clinical efficacy of patients with advanced cervical cancer， and does not increase the adverse reactions compared to docetaxel alone.